Marek Poszepczynski

Fund Manager

2023

I am Fund Manager at Schroders responsible for International Biotechnology Trust, a ~400m$ AUM London based Investment Trust. My main tasks are to evaluate global pharma, biotech and other life sciences investment opportunities and invest in the best opportunities accordingly. The team has had good long term performance.

Co-Founder

2013

Lead Investment Manager

2017 - 2024

I am Lead Investment Manager at International Biotechnology Trust, a ~400m$ AUM London based Investment Trust and acting Investment Manager. My main tasks are to evaluate global pharma, biotech and other life sciences investment opportunities and invest in the best opportunities accordingly. The team has had good performance. In my spare time I support start-ups and growing biotech companies with their licensing preparations, negotiations, valuations and transactions i.e. the whole process from inception to closing, including task such as market assessments, development strategies and competition.

IBT Consultant and investment analyst

2014 - 2017

International Biotechnology Trust (SV Life Sciences) is a London based Investment Trust listed on the London Stock Exchange. I was and am part of the investment group responsible for the publicly traded companies in the fund. My major tasks consist of evaluating global pharma/biotech opportunities and recommend investments from fundamental, M&A and business development perspectives. The fund was awarded the UK Tech Award 2015 and Investor Chronicle FT 2015, Best Specialist Fund A part of my time I dedicate to support biotech companies with licensing and strategy support, I am also adviser in two high rank corporate finance institutions.

Senior Business Development Director

2012 - 2017

Being in charge of the business development activities at Pharmalink encompasses all business oriented tasks; from basic every day project related issues to late stage negotiations and financing. My main objectives are to co-ordinate, position and see the process through the projects being out-licensed to the pharmaceutical industry. A successful deal is highly dependent on quality and timing in all stages of a licensing process in this complex industry. In parallel to my business development job, I support start-ups and growing biotech companies with their licensing preparations.

Co-founder and board member

2008 - 2015

Lead analyst (Pharma and Biotechnlogy)

2010 - 2012

Lead analyst, Pharma & Biotech, Handelsbanken Capital Markets The primary objective in the position was to provide fund managers and other clients, with deep analysis of the life science sector to support investment decisions. Being an analyst included a high proportion of communication, both internally and externally, especially in the science focused biotech companies. The bulk of the job was committed to company and product research, through own studies, discussions with key opinion leaders but also with top management of the companies in my coverage universe. IPOs and other financial activities were also an integral part of the role.

VP Business Development

2008 - 2010

My main role in the position was to streamline business operations in the portfolio companies which Karolinska Development were had majority stakes. The focus was to make the portfolio companies more business oriented. This meant a lot of hands-on, operational work together with management and owners. It included fund-raising, negotiations and other potential financial activities, such as licensing and M&A activities. The other part of the position included evaluations of new investment opportunities and out-licensing of some of the current portfolio companies. I was acting as VP Business Development in a handful of the relatively late stage companies and board member in several others.

Director Corporate Development

2005 - 2008

During the three years that I was part of the corporate development team, which was responsible for in- and out-licensing of the company’s R&D portfolio. My main responsibilities were to construe new and innovative ways to match out-licensors demands and our wishes to make a deal designed to create an understanding for when and who will take on risks and rewards accordingly. I was also responsible for the in-licensing deal-flow. Negotiations, valuations and due diligences and market surveys to understand market dynamics in detail were essential and a party of my daily activities.

Group Financial Controller

2003 - 2005

During these two years I was responsible for the financial operations concerning Biovitrums Contract-/Sales division. The work included everything from forecasting to strategic review and planning. My advanced knowledge in financial mathematics led to a high degree of involvement in questions regarding M&As, valuations and financial securities. In addition to that I was also responsible for the build-up and modelling of Biovitrums strategy